Menu

First Dengue Vax Approved

Mexico’s health ministry has OKed the vaccine for people between nine and 45 years old.

Dec 11, 2015
Kerry Grens

FREE STOCK PHOTOS, CDC/PROF FRANK HADLEY COLLINSMexico has approved the world’s first dengue virus vaccine. Sanofi’s Dengvaxia will be available to children over nine and adults 45 and under.

“We are making dengue a preventable disease, which makes us incredibly proud,” Olivier Charmeil, the head of vaccines at Sanofi, told Bloomberg Business.

According to the World Health Organization, 2.35 million people in the Americas contracted the mosquito-borne illness in 2013. Dengue can cause high fever, muscle pains, vomiting, and, in some cases, death.

Sanofi spent two decades and $1.6 billion on the development of Dengvaxia. According to BBC News, about 40,000 people in Mexico will initially receive the shot. “With this decision, Mexico moves ahead of all other countries, including France, to tackle the spread of this virus,” the country’s health ministry in a statement.

Results of a clinical trial among children found the vaccine is about 60 percent effective at warding off dengue virus.

The price of the immunization has not been disclosed. More than a dozen other countries are considering approval, according to Bloomberg News.

Update (December 29): Health officials in Brazil and the Philippines have also approved the use of Dengvaxia, Sanofi Pasteur announced over the past week.

“Approval of the first dengue vaccine is an important public health breakthrough with critical importance to our country, which bears the greatest dengue burden in Latin America,” Joao Bosco Siqueira Junior of the Federal University of Goias, Brazil, said in the press release.

Dengue cases in Brazil erupted in 2015, topping 1.5 million, compared to roughly 500,000 in 2014, The Wall Street Journal reported. Asia, however, bears the brunt of dengue fever, with 70 percent of infections occurring there.

It’s not clear when the vaccine will become available in the countries that have authorized its distribution.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.